<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
27505-006-01
</NDCCode>
<PackageDescription>
5 CARTRIDGE in 1 CARTON (27505-006-01) / 20 mL in 1 CARTRIDGE (27505-006-05)
</PackageDescription>
<NDC11Code>
27505-0006-01
</NDC11Code>
<ProductNDC>
27505-006
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Onapgo
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Apomorphine Hydrochloride
</NonProprietaryName>
<DosageFormName>
INJECTION, SOLUTION
</DosageFormName>
<RouteName>
SUBCUTANEOUS
</RouteName>
<StartMarketingDate>
20250204
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
NDA
</MarketingCategoryName>
<ApplicationNumber>
NDA214056
</ApplicationNumber>
<LabelerName>
MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc
</LabelerName>
<SubstanceName>
APOMORPHINE HYDROCHLORIDE
</SubstanceName>
<StrengthNumber>
4.9
</StrengthNumber>
<StrengthUnit>
mg/mL
</StrengthUnit>
<Pharm_Classes>
Dopamine Agonists [MoA], Dopaminergic Agonist [EPC]
</Pharm_Classes>
<DEASchedule/>
<Status>
Deprecated
</Status>
<LastUpdate>
2025-04-02
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20261231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20250204
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>